 Primary Myelofibrosis
"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Descriptor ID |
D055728
|
| MeSH Number(s) |
C15.378.190.636.765
|
| Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Fibrosis, Bone Marrow
- Myelofibrosis With Myeloid Metaplasia
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Myelofibrosis
- Myelofibroses
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in UAMS Profiles by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2023 | 3 | 0 | 3 | | 2022 | 1 | 0 | 1 | | 2021 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles over the past ten years.
-
Ibrahim M, Murphree C, Patel K, Mastrodomenico M, Saba NS, Safah H, Schmid J, Socola F. Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2054.
-
Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a?comparative analysis of phenotype and survival. Blood Adv. 2023 06 27; 7(12):2694-2698.
-
Al-Ghamdi YA, Lake J, Bagg A, Thakral B, Wang SA, Bueso-Ramos C, Masarova L, Verstovsek S, Rogers HJ, Hsi ED, Gralewski JH, Chabot-Richards D, George TI, Rets A, Hasserjian RP, Weinberg OK, Parilla M, Arber DA, Padilla O, Orazi A, Tam W. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
-
Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, Tefferi A. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023 01 04; 13(1):3.
-
Yenwongfai LN, Arora R, Smith AP, Kalfa T, Husami A, Radulescu V, Myers K, Lorsbach R. Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry. Pediatr Blood Cancer. 2023 03; 70(3):e30023.
-
Gangat N, McCullough K, Al-Kali A, Begna KH, Patnaik MM, Litzow MR, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Palmer JM, Pardanani A, Tefferi A. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20?mg twice daily or higher: A real-world experience. Br J Haematol. 2022 08; 198(4):e54-e58.
-
Green SE, Singh ZN, Baer MR. Primary myelofibrosis in a patient with sickle cell disease. Am J Hematol. 2022 01 01; 97(1):160-161.
-
Mojica AM, Wolfe AD. A Case of Myelofibrosis and Myelodysplasia Identified Following Exposure to Isotretinoin. J Pediatr Hematol Oncol. 2021 01; 43(1):e136-e137.
-
Shah RK, Munson M, Wierenga KJ, Pokala HR, Newburger PE, Crawford D. A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis. Pediatr Blood Cancer. 2017 Sep; 64(9).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|